Hanall Biopharma (009420) — Free Cash Flow Generation Index
Hanall Biopharma (009420) has a Free Cash Flow Generation Index of 0.55x as of September 2025. Free cash flow of ₩4.07 Billion represents 1% of operating cash flow (₩7.34 Billion). See Hanall Biopharma (009420) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Hanall Biopharma Free Cash Flow Generation Index (2011–2024)
Historical FCF Generation Index trend for Hanall Biopharma across 10 annual periods. Explore 009420 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for Hanall Biopharma (2011–2024)
Year-by-year Free Cash Flow Generation Index for Hanall Biopharma. For the full company profile including market capitalisation, see 009420 company net worth.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.46x | ₩-13.71 Billion | ₩9.36 Billion | ₩23.07 Billion | ▼ -312.3% |
| 2023 | 0.69x | ₩20.45 Billion | ₩29.64 Billion | ₩9.20 Billion | ▼ -0.8% |
| 2022 | 0.70x | ₩17.53 Billion | ₩25.20 Billion | ₩2.83 Billion | ▲ +107.2% |
| 2021 | -9.72x | ₩-8.16 Billion | ₩839.87 Million | ₩4.61 Billion | ▼ -39.8% |
| 2020 | -6.95x | ₩-6.46 Billion | ₩929.29 Million | ₩2.56 Billion | ▼ -1266.2% |
| 2019 | 0.60x | ₩12.22 Billion | ₩20.49 Billion | ₩2.12 Billion | ▼ -37.1% |
| 2017 | 0.95x | ₩39.93 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -53.1% |
| 2016 | 2.02x | ₩7.98 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +1.3% |
| 2012 | 1.99x | ₩4.38 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +88.6% |
| 2011 | 1.06x | ₩7.84 Billion | ₩7.41 Billion | ₩426.70 Million | — |